Ginkgo Bioworks Corp. - רווח נקי למניה (EPS TTM) DNA

Ginkgo Bioworks Holdings (DNA) is undergoing a stage of image stabilization and internal restructuring due to declining revenues. The rolling unit profit metric visualizes this trend, where the -4.60 mark serves as the current indicator. Ginkgo Bioworks Holdings (DNA) relies on the creation of an AI environment for cell coding in partnership with Google, generating revenue through licenses. Its status as a synthetic biology visionary ensures government confidence in its developments.
פילוחים אנליטיים ודוחות נתונים של חברת Ginkgo Bioworks Holdings (DNA)

For asset stress testing, it is critical for investors to analyze EPS TTM as the final result of dividing total annual net income by the total number of shares. As Ginkgo Bioworks Holdings (DNA) shifts toward organic restructuring and a reduction in M&A, the company's trailing 12-month earnings per share clearly demonstrates the effectiveness of cost optimization and the monetization of technological contracts with pharma behemoths.